CytoReason vs DPEEX
CytoReason vs DPEEX, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and DPEEX on 52/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 52/100
- headcount: 116 against 4
- LinkedIn following: 12,830 against 229
DPEEX
Leads on none of the measures we hold for both companies.
At a glance
| Measure | CytoReason | DPEEX |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | AI-powered multi-omics platform for early breast cancer detection and risk prediction. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Cancer, Life Sciences, HealthTech |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Platform |
| Founded | 2016 | 2017 |
| Headquarters | Tel Aviv, Israel | Not published |
| Status | Active | Inactive |
Size, funding and growth
| Measure | CytoReason | DPEEX |
|---|---|---|
| Employees | 116 | 4 |
| Headcount growthLast 12 months | +13.7% | Not published |
| Total funding | $128M | Not published |
| Latest round | Series B | Not published |
| LinkedIn followers | 12,830 | 229 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | DPEEX |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 52/100 |
| Traction | 60/100 | 42/100 |
| Team | 70/100 | 70/100 |
| Community | Not published | 15/100 |
| Search visibility | 30/100 | 29/100 |
| Quality | 78/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | F (22/100) |
| Domain ratingLink authority, 0-100 | 40/100 | Not published |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | DPEEX |
|---|---|---|
| Analytics | Segment | Not detected |
CytoReason vs DPEEX: common questions
Which is better, CytoReason or DPEEX?
On our 0-100 score CytoReason rates higher (68/100 against 52/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do CytoReason and DPEEX compare on the numbers?
CytoReason leads on our overall score (68/100 against 52/100), headcount (116 against 4), LinkedIn following (12,830 against 229).
Read the full CytoReason review and pricing or the DPEEX review and pricing. You can also browse other CytoReason alternatives we track.